Advertisement
EDIT vs ROP
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a StrongBuy and ROP is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 0 FA rating(s) are green whileROP’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 0 green, 5 red.
- ROP’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 5 TA indicator(s) are bullish while ROP’s TA Score has 3 bullish TA indicator(s).
- EDIT’s TA Score: 5 bullish, 4 bearish.
- ROP’s TA Score: 3 bullish, 4 bearish.
Price Growth
EDIT (@Biotechnology) experienced а +17.33% price change this week, while ROP (@Packaged Software) price change was -1.70% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +3.11%. For the same industry, the average monthly price growth was +11.57%, and the average quarterly price growth was +67.25%.
The average weekly price growth across all stocks in the @Packaged Software industry was +8.94%. For the same industry, the average monthly price growth was +4.32%, and the average quarterly price growth was +120.09%.
Reported Earning Dates
EDIT is expected to report earnings on Nov 10, 2025.
ROP is expected to report earnings on Oct 22, 2025.
Industries' Descriptions
@Biotechnology (+3.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
@Packaged Software (+8.94% weekly)Packaged software comprises multiple software programs bundled together and sold as a group. For example, Microsoft Office includes multiple applications such as Excel, Word, and PowerPoint. In some cases, buying a bundled product is cheaper than purchasing each item individually[s20] . Microsoft Corporation, Oracle Corp. and Adobe are some major American packaged software makers.
| EDIT | ROP | EDIT / ROP | |
| Capitalization | 291M | 53.7B | 1% |
| EBITDA | -227.72M | 3.1B | -7% |
| Gain YTD | 177.165 | -3.200 | -5,536% |
| P/E Ratio | N/A | 35.18 | - |
| Revenue | 38.9M | 7.47B | 1% |
| Total Cash | 179M | 242M | 74% |
| Total Debt | 21.1M | 8.86B | 0% |
EDIT | ROP | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 19 | 63 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 69 Overvalued | 24 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 62 | |
SMR RATING 1..100 | 99 | 77 | |
PRICE GROWTH RATING 1..100 | 36 | 63 | |
P/E GROWTH RATING 1..100 | 100 | 67 | |
SEASONALITY SCORE 1..100 | 16 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ROP's Valuation (24) in the Industrial Conglomerates industry is somewhat better than the same rating for EDIT (69) in the Biotechnology industry. This means that ROP’s stock grew somewhat faster than EDIT’s over the last 12 months.
ROP's Profit vs Risk Rating (62) in the Industrial Conglomerates industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that ROP’s stock grew somewhat faster than EDIT’s over the last 12 months.
ROP's SMR Rating (77) in the Industrial Conglomerates industry is in the same range as EDIT (99) in the Biotechnology industry. This means that ROP’s stock grew similarly to EDIT’s over the last 12 months.
EDIT's Price Growth Rating (36) in the Biotechnology industry is in the same range as ROP (63) in the Industrial Conglomerates industry. This means that EDIT’s stock grew similarly to ROP’s over the last 12 months.
ROP's P/E Growth Rating (67) in the Industrial Conglomerates industry is somewhat better than the same rating for EDIT (100) in the Biotechnology industry. This means that ROP’s stock grew somewhat faster than EDIT’s over the last 12 months.
| EDIT | ROP | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 52% |
| Momentum ODDS (%) | 2 days ago 74% | 2 days ago 47% |
| MACD ODDS (%) | 2 days ago 89% | 2 days ago 49% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 41% |
| TrendMonth ODDS (%) | 2 days ago 80% | 2 days ago 48% |
| Advances ODDS (%) | 2 days ago 78% | 2 days ago 43% |
| Declines ODDS (%) | 16 days ago 89% | 12 days ago 43% |
| BollingerBands ODDS (%) | 2 days ago 89% | 2 days ago 45% |
| Aroon ODDS (%) | N/A | 2 days ago 43% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| MAMB | 23.76 | 0.19 | +0.79% |
| Monarch Ambassador Income ETF | |||
| LGH | 60.05 | 0.21 | +0.35% |
| HCM Defender 500 Index ETF | |||
| FOWF | 31.03 | 0.05 | +0.16% |
| Pacer Solactive Whitney Fut of Wrfr ETF | |||
| BBIB | 99.61 | N/A | N/A |
| JPMorgan BetaBuilders U.S.TrsBd3-10YrETF | |||
| FDL | 43.07 | -0.30 | -0.69% |
| First Trust Morningstar Div Leaders ETF | |||
ROP and
Correlation & Price change
A.I.dvisor indicates that over the last year, ROP has been closely correlated with AME. These tickers have moved in lockstep 75% of the time. This A.I.-generated data suggests there is a high statistical probability that if ROP jumps, then AME could also see price increases.